REGENXBIO Inc. (RGNX) Earnings Call Transcripts
REGENXBIO Inc.'s Latest Earnings Call - May 20, 2026
In the Q1 2026 earnings call, REGENXBIO Inc. (RGNX:US) provided updates on its Duchenne muscular dystrophy (DMD) program and regulatory strategy, which could significantly impact the stock. The company plans to initiate its Biologics License Application (BLA) filing in Q3 2026, with completion expected by Q1 2027. Management highlighted strong top-line data supporting accelerated approval, despite some concerns around safety events reported in the trial. Revenue and earnings details were not disclosed in the call, but management's confidence in the regulatory pathway signals potential for future growth.
Reported metrics
| Metric | Value |
|---|---|
| BLA Filing Timeline | Q3 2026 (positive) |
| Serious Adverse Events | 2 (neutral) |
| Functional Assessments | 9 patients reported (positive) |
| Market Position | Differentiated (positive) |
| Trial Powering | 80% (positive) |
| Hunter Program Status | Clinical hold lifted (positive) |
Guidance from management
Management is focused on initiating the BLA filing for DMD in Q3 2026 and completing it by Q1 2027, indicating a strong commitment to advancing their regulatory strategy.
What management said
Absolutely. So we, in real time, continue to get patients through their 12-month assessment. So what you saw in the data set was safety on all 30 patients, or 31 actually in the study. You saw microdystrophin levels for all of those patients. And then the functional assessments, keep in mind, we finished enrollment late October, early November of last year. Those patients' 12-month data point won't occur until later ...
Correct. And then what we've seen in our Phase I/II data historically is that roughly an 80% reduction overall in treatment burden, so less injections. If we're near those values in our pivotal setting, then we feel like we've met our target product profile, and this is on its way to hopefully a commercialization effort.
What analysts pressed on
Analysts expressed concerns regarding the timing of the BLA submission and the implications of the reported SAEs on regulatory approval. There is also apprehension about the competitive landscape and the need for robust data to support claims of safety and efficacy.
Main topics on the call
- Regulatory Strategy for DMD — Management emphasized the importance of waiting for new FDA leadership before submitting data for DMD, stating, "We think the top line data checks every box that you need for accelerated approval." They plan to begin fil...
- Safety Concerns — The call addressed two serious adverse events (SAEs) reported in the DMD trial, with management stating, "Those were resolved without sequelae, so fairly easily managed." They believe their safety profile is superior to ...
- Functional Data and Patient Outcomes — Management noted that while functional data was available for only 9 patients, they expect this number to double as more patients reach their 12-month assessments. They highlighted that some patients showed improvement b...
- Competitive Landscape — Management discussed the competitive environment, noting that their product is differentiated from others like ELEVIDYS due to its manufacturing control and safety profile. They stated, "We feel confident we're in good s...
Read the full REGENXBIO Inc. transcript (May 20, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About REGENXBIO Inc.
REGENXBIO Inc. (RGNX) is a publicly listed company in the Biotechnology industry, within the Health Care sector. It trades on NasdaqGS and is based in US. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 76 calls on record spanning February 26, 2020 to August 6, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.
Earnings Call History
EarningsCalls.dev has 76 REGENXBIO Inc. earnings call transcripts on record, spanning February 26, 2020 to August 6, 2026. Based on this history, REGENXBIO Inc. reports quarterly. The most recent call on file is dated August 6, 2026. The full list is below — each row opens the complete, free-to-read transcript.
- Ticker
- RGNX
- Exchange
- NasdaqGS
- Country
- US
- Sector
- Health Care
- Industry
- Biotechnology
- Calls on record
- 76
- First call
- February 26, 2020
- Most recent
- August 6, 2026
- Reporting cadence
- quarterly